Enliven Therapeutics: Preclinical Company With Interesting Value Proposition (NASDAQ:ELVN)


Hands growing a young plant

andreswd/E+ via Getty Images

Largely speaking, every other early stage biopharma I cover starts out with a candidate targeting some form of leukemia/lymphoma. Here’s one more to add to that list – Enliven Therapeutics, Inc. (NASDAQ:ELVN) – a



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *